C/EBPβ Expression Is Predictor of Survival in Breast Cancer Patients
Ewa Kurzejamska, Karin Jistrom, Piotr Religa. Karolinska Institutet, Stockholm, Sweden; Lund University, Lund, Sweden
Background: C/EBPβ is a transcription factor playing a critical role in mammary gland development and breast cancer progression. Recent studies show that loss of C/EBPβ contributes to progression of lymphoma In this study, we analyzed the prognostic significance of C/EBPβ expression in metastatic breast cancer.
Design: Tissue microarray (TMA) study was performed on 137 metastatic breast cancer patients. Using immunohistochemistry, the intensity of C/EBPβ staining was evaluated and compared with relevant clinicopathological characteristics. Cox proportional hazards models and Kaplan-Meier analysis were used to assess the effect of C/EBPβ expression on overall survival (OS) in univariate and multivariate analysis, adjusted for established prognostic factors.
Results: All parameters were assessed in univariate models using Cox proportional hazards models and factors significant at p<0.05 were included in the final model. In multivariate analysis, independent predictors of overall survival (OS) were C/EBPβ expression (hazard ratio [HR] 0.2453; 95% confidence interval [CI] 0.08 to 0.72; P=0.011), age (HR 1.1; 95% CI 1.06 to 1.46; P<0.0001) and chemotherapy (HR 6.3; 95% CI 1.82 to 21.82; P=0.004). Moreover, Kaplan-Meier survival analysis showed that C/EBPb expression is significantly associated with overall survival (P=0.004), but also related to relapse-free survival (RFS).
Conclusions: Presented results indicate that C/EBPβ expression in breast cancer is an independent predictor of OS in metastatic breast cancer patients.
Wednesday, March 6, 2013 1:00 PM
Poster Session VI # 11, Wednesday Afternoon